Myovant Sciences is a biopharmaceutical company focused on redefining care for women and for men. Co.'s product and product candidates consist of: Relugolix, which is a molecule that acts as a gonadotropin-releasing hormone receptor antagonist, a treatment for uterine fibroids, endometriosis, prevention of pregnancy and advanced prostate cancer; ORGOVYX, which is an oral gonadotropin-releasing hormone receptor antagonist for men with prostate cancer; and MVT-602, which is an oligopeptide kisspeptin-1 receptor agonist, being developed as a potential treatment for female infertility in women as part of assisted reproduction, such as in vitro fertilization. The MYOV stock yearly return is shown above.
The yearly return on the MYOV stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MYOV annual return calculation with any dividends reinvested as applicable (on ex-dates).
|